In different districts, overexpression of beta-tubulin-3 in cancer cells has been associated with resistance to docetaxel-based chemotherapy in patients with advanced cancer [5,6] and recent inhibitors targeting the c-Myc pathways has been proposed. This evidence concerns the gene TUBB3 and cancer.